Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ EDG4 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA597931
Description
EDG4 Polyclonal Antibody for Western Blot, IHC (P), ELISA
Edg4 is a Lysophospholipid/Lysosphingolipid Receptor activated by phosphatidic acid (PA) and lysophosphatidic acid (LPA). It enhances the transcription of serum response element (SRE) reporter genes. In CD4(+) T cells, Edg4 may be involved in the control of interleukin-2 secretion. Edg4 expression has been documented in leukocytes, pancreas, spleen, thymus, prostate, and testis. Edg4 expression has also been seen in many cancer cell lines, including those of brain, blood, breast, ovary, cervix, colon, skin, and thyroid. ESTs have been isolated from B-cell/lung/testis, blood, brain, embryo, heart/melanocyte/uterus, liver, placenta, prostate, and skin libraries.
Specifications
EDG4 | |
Polyclonal | |
Unconjugated | |
LPAR2 | |
Edg4; EDG-4; endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor 4; endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 4; G protein-coupled receptor; IPA2; LPA receptor 2; LPA receptor EDG4; LPA2; LPA-2; LPA2 Receptor; LPAR2; Lysophosphatidic acid receptor 2; lysophosphatidic acid receptor EDG4; lysophosphatidic acid receptor Edg-4; Pbx4; pre-B-cell leukemia transcription factor 4; RGD1561336 | |
Rabbit | |
Protein G | |
RUO | |
9170 | |
-20°C or -80°C if preferred | |
Liquid |
ELISA, Immunohistochemistry (Paraffin), Western Blot | |
4.205 mg/mL | |
PBS with 50% glycerol and 0.03% ProClin 300; pH 7.4 | |
Q9HBW0 | |
LPAR2 | |
Peptide sequence from Human Lysophosphatidic acid receptor 2 protein (8-27AA). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction